SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalGeron Corp.


Previous 10 Next 10 
From: Savant11/19/2021 10:55:10 AM
   of 3545
 
Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as an inducement to a newly hired employee in connection with commencement of employment with the Company.

The stock option was granted on November 17, 2021 at an exercise price of $1.42 per share, which is equal to the closing price of Geron common stock on the date of grant. The stock option has a 10-year term and vests over four years, with 12.5% of the shares underlying the option vesting on the six-month anniversary of commencement of employment and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates. The option was granted as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and is subject to the terms and conditions of the stock option agreement covering the grant and Geron's 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com.

Share RecommendKeepReplyMark as Last Read


To: cycleupcycledown who wrote (3510)12/18/2021 5:05:11 PM
From: Aloner
   of 3545
 
So, how's that workin' out for ya?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


From: tktrimbath12/31/2021 8:19:33 PM
1 Recommendation   of 3545
 
My end of year review of GERN

INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.

Geron

GERN (market cap is $0.393B was $0.495B)

Geron is a leading edge biotech focused on telomerase treatments dealing with hematological treatments. They continue to make progress to the point that some estimates of more general use are described in a few years rather than the decades it has taken so far. As with many innovative treatments aimed at a narrow portion of a broader illness, approval for one treatment can lead to a multiplying effect as it is applied to similar illnesses. First, fix one.

Geron was working on a wide variety of innovative treatments for decades. They sold off almost everything else. If successful, they may be a headline comeback story and benefit people dealing with few if any options.

I suspect investors familiar with the company and the technology over these years may be sitting and watching for significant, positive news. The company forecasts the commercial launch of imetelstat in lower risk MDS in the United States to be in 2024. Investors won't all wait until full approval, but it is hard to know when or if they will return, hence, I buy now and hold.



DISCLOSURE LTBH since 1999 and continuing to hold. I bought more when they mentioned specific years for clinical trials and approval goals.

(I've also collected links to the other discussion boards and my other stocks over on my blog trimbathcreative.net )

Share RecommendKeepReplyMark as Last Read


To: Aloner who wrote (3522)2/20/2022 11:32:58 PM
From: cycleupcycledown
   of 3545
 
I bailed months ago.....Back in last week, fire sale, $1.05

Share RecommendKeepReplyMark as Last Read


From: cycleupcycledown2/24/2022 10:26:41 PM
   of 3545
 
Dumb luck, caught bottom?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: cycleupcycledown who wrote (3525)2/26/2022 12:21:50 PM
From: tktrimbath
   of 3545
 
Skill, pure skill. Congratulations.

Share RecommendKeepReplyMark as Last Read


From: cycleupcycledown2/28/2022 12:04:18 PM
   of 3545
 
Call me tommy telomeres

Share RecommendKeepReplyMark as Last Read


From: cycleupcycledown3/18/2022 11:22:20 PM
   of 3545
 
March 10 earnings call was encouraging, positive.....Big plans in a couple of years.

Share RecommendKeepReplyMark as Last Read


From: cycleupcycledown3/30/2022 10:13:15 AM
   of 3545
 
Thought I was gonna get cut up today after dilution news, but she's up instead

Share RecommendKeepReplyMark as Last Read


From: cycleupcycledown3/30/2022 11:05:36 PM
   of 3545
 
Don't know the short situation, more fuel later............be so cool if those young whippersnappers on msg boards catch wind.

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10